Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-year-old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report

5Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Introduction: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of multisystemic autoim-mune diseases that can involve organs such as kidneys and respiratory tracts. Since the initiation of COVID-19 vaccines, there have been few cases of antineutrophil cytoplasmic antibody (ANCA) glomerulonephritis development after receiving vaccine doses. Case Presentation: This report describes a 15-year-old man who has developed ANCA-associated glomerulonephritis (AAGN) after receiving the second dose of BBIBP-CorV (Sinopharm) COVID-19 vaccine. Conclusions: Development of AAGN after both natural SARS-CoV-2 infection and following other vaccinations raises the question of the possible causality between the two. Considering the widespread use of COVID-19 vaccines, it is highly important to investigate their possible side effects.

Cite

CITATION STYLE

APA

Ramezanzade, E., Ghanbari, R., & Yazdanipour, T. (2022). Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-year-old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report. Nephro-Urology Monthly, 14(3). https://doi.org/10.5812/numonthly-127124

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free